Statistics on Biotechnology Use  
Results by sector of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total;
No. of companies carrying out R&D in Biotechnology;975;81;1.056;
%Companies according to biotechnology used: Genetic code;35;46;36;
%Companies according to biotechnology used: Functional units;44;50;45;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;26;45;27;
%Companies according to biotechnology used: Bioprocesses;45;66;47;
%Companies according to biotechnology used: Sub-cellular organisms;8;15;8;
%Companies according to biotechnology used: Bio-computing;24;32;25;
%Companies according to biotechnology used: Nanobiotechnology;13;16;13;
%Companies according to biotechnology used: Other;15;13;15;
Companies in which biotechnology activities are: Main and/or exclusive;538;12;551;
Companies in which biotechnology activities are: A secondary line of business;164;19;183;
Companies in which biotechnology activities are: A tool necessary for production;273;50;323;
%Company by field(s) of ultimate application of biotechnology use: Human Health;49;52;49;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;22;3;20;
%Company by field(s) of ultimate application of biotechnology use: Food products;30;36;30;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;23;13;23;
%Company by field(s) of ultimate application of biotechnology use: Environment;13;17;13;
%Company by field(s) of ultimate application of biotechnology use: Industry;13;7;12;
Personnel in R&D in biotechnology (no. of persons);7.908;2.811;10.719;
Personnel in R&D in biotechnology (no. of persons): Researchers;4.660;1.470;6.131;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;3.247;1.341;4.588;
Personnel in R&D in biotechnology (no. of persons): women;4.291;1.749;6.040;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.520;891;3.411;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;1.772;857;2.629;
Personnel in R&D in biotechnology (FTE);5.651,3;2.099,5;7.750,8;
Personnel in R&D in biotechnology (FTE): Researchers;3.461,8;1.056,3;4.518,1;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.189,4;1.043,3;3.232,7;
Personnel in R&D in biotechnology (FTE): women;3.133,9;1.337,5;4.471,4;
Personnel in R&D in biotechnology (FTE): (women) Researchers;1.912;650,7;2.562,7;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.221,9;686,8;1.908,7;
Internal expenditure on R&D (thousands of euros);511.004;168.555;679.558;
1) By nature of the expense: Current expenses;470.651;163.981;634.631;
1.1) Remuneration to researchers;167.208;61.649;228.857;
1.2) Remuneration to technicians and assistants;63.658;40.840;104.498;
1.3) Other current expenses;239.785;61.492;301.276;
2) By nature of the expense: Capital expenses;40.353;4.574;44.927;
2.1) Land and buildings;2.519;66;2.585;
2.2) Equipment and instruments;19.828;3.741;23.569;
2.3) Acquisition of specific R&D software;780;612;1.392;
2.4) Otros productos de propiedad intelectual específicos para I+D;17.226;155;17.381;
1) By origin of the funds: National funds;417.983;138.313;556.297;
1.1) Own funds;301.946;85.064;387.010;
1.2) From companies;49.801;36.223;86.025;
1.3) Public Administration funds;61.218;13.546;74.764;
1.4) From Universities;408;0;408;
1.5) From non profit private institutions;4.610;3.480;8.090;
1) By origin of the funds: Foreign funds;93.020;30.241;123.262;
2.1) From EU programmes;18.993;6.132;25.125;
2.2) Other foreign funds;74.027;24.109;98.137;
Purchase of R&D services in biotechnology (thousands of euros);86.267;61.292;147.558;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;26.503;50.373;76.875;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;59.764;10.919;70.683;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;50;25;49;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;14;11;14;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;16;15;16;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;13;15;13;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;18;13;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;19;8;18;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;17;14;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;38;30;37;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;52;40;51;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;18;14;18;
% Companies that have requested biotechnology patents in Biotechnology;15;16;16;
Number of patents requested;602;144;746;
% Companies with income of an international origin related to biotechnological activities;23,9;16;23,3;
% Turnover representing income of an international origin related to biotechnological activities;5,7;0,7;1,2;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;49,3;69,7;60,4;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;50,7;30,3;39,6;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;92,6;71,2;80,9;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;5,5;27,9;17,8;
% Income of an international origin related with activities according to the classification: Operating source abroad;1,9;0,8;1,3;
% Income of an international origin related with activities according to the classification: Other;0,1;.;0,1;
Notas:

.
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute